Phase I/II study of novel oral fluoropyrimidine S-1 in combination with oxaliplatin (SOX) as first-line chemotherapy for metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Tahara, M. [1 ]
Yamada, Y. [2 ]
Ohtsu, A. [1 ]
Shirao, K. [2 ]
Shimada, Y. [2 ]
Sasaki, Y. [3 ]
Yamamoto, W. [3 ]
Satoh, T. [4 ]
Okamoto, W. [4 ]
Tanigawara, Y. [5 ]
机构：
[1] Natl Canc Ctr Hosp E, Div Endoscopy & GI Oncol, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr, Gastrointestinal Oncol Div, Tokyo, Japan
[3] Saitama Med Univ Int, Med Ctr, Dept Clin Oncol, Saitama, Japan
[4] Kinki Univ, Sch Med, Dept Med Oncol, Osaka, Japan
[5] Keio Univ Hosp, Dept Pharm, Tokyo, Japan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70989-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3061
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [41] PHASE II STUDY OF S-1, ORAL LEUCOVORIN, OXALIPLATIN AND BEVACIZUMAB COMBINATION THERAPY (SOL plus BV; SOLA) IN PATIENTS WITH UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Miyata, Y.
    Nishina, T.
    Kato, T.
    Yamazaki, K.
    Yoshino, T.
    Esaki, T.
    Moriwaki, T.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 131 - 131
  • [42] Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study
    Lapeyre-Prost, A.
    Pernot, S.
    Sigrand, J.
    Mary, F.
    Le Malicot, K.
    Aparicio, T.
    Dahan, L.
    Caroli-Bosc, F-X.
    Lecomte, T.
    Doat, S. Racine
    Marthey, L.
    Desrame, J.
    Lepage, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 160 - 160
  • [43] A phase I study of cetuximab (cet) in combination with S-1 and irinotecan (iri) (SIRC) in first-line treatment for metastatic colorectal cancer (mCRC) (JACCRO CC-10).
    Tsuji, Akihito
    Nakamura, Masato
    Masuishi, Toshiki
    Kotaka, Masahito
    Shimada, Ken
    Kochi, Mitsugu
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [44] Phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL plus BV; SOLA) in patients with unresectable metastatic colorectal cancer (mCRC).
    Kato, Takeshi
    Nishina, Tomohiro
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Miyata, Yoshinori
    Esaki, Taito
    Moriwaki, Toshikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [45] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [46] A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)
    Maroun, Jean A.
    Jonker, Derek
    Goel, Rakesh
    Cripps, Christine
    Lister, Diane
    Chiritescu, Gabriela
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [47] JAPANESE COHORT STUDY OF FIRST LINE CHEMOTHERAPY (CT) FOR METASTATIC COLORECTAL CANCER (MCRC) CONTAINING FLUOROPYRIMIDINE, OXALIPLATIN AND BEVACIZUMAB: EMERALD STUDY, FIRST REPORT
    Taku, K.
    Ohata, K.
    Yamazaki, K.
    Nishikawa, G.
    Watanabe, M.
    Sato, S.
    Oshima, T.
    Hirano, H.
    Amano, T.
    Ohashi, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 220 - 220
  • [48] Final results of phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL plus BV; SOLA) in metastatic colorectal cancer (mCRC).
    Yamazaki, Kentaro
    Nishina, Tomohiro
    Kato, Takeshi
    Yoshino, Takayuki
    Miyata, Yoshinori
    Esaki, Taito
    Moriwaki, Toshikazu
    Boku, Narikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [49] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Yoshito Komatsu
    Chikashi Ishioka
    Ken Shimada
    Yasuhide Yamada
    Makio Gamoh
    Atsushi Sato
    Tatsuro Yamaguchi
    Satoshi Yuki
    Satoshi Morita
    Shin Takahashi
    Rei Goto
    Minoru Kurihara
    BMC Cancer, 15
  • [50] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Komatsu, Yoshito
    Ishioka, Chikashi
    Shimada, Ken
    Yamada, Yasuhide
    Gamoh, Makio
    Sato, Atsushi
    Yamaguchi, Tatsuro
    Yuki, Satoshi
    Morita, Satoshi
    Takahashi, Shin
    Goto, Rei
    Kurihara, Minoru
    BMC CANCER, 2015, 15
12345